Monte Rosa
Monte Rosa Therapeutics is a biotechnology company that develops cancer therapeutics that modulate protein degradation pathways.
Monte Rosa has raised €80M across 1 funding round from 1 investor, most recently a Series C round in Mar 2021. Based in Basel, Switzerland; founded 2018; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€80M
€79,946,142
Funding rounds
1
Investors
1
distinct backers
Active since
2021-03
latest 2021-03
Funding by year
EUR raised per yearMonte Rosa — funding by year — interactive chart.
Data table
| Monte Rosa — funding by year | |
|---|---|
| 2021 | €80M |
Signals
High confidenceRaise-next likelihood9
base rate 50% for Series C
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-03-24 | Series C | €80M | Avoro Capital Advisors | View deal → |
Investors
1Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Climeworks€919MSwitzerland · Cleantech
Global coverage: FundingData